- Home
- CZNC vs CMPS Comparison
CZNC vs CMPS Comparison
Compare CZNC & CMPS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CZNC
- CMPS
- Stock Information
- Founded
- CZNC 1864
- CMPS 2020
- Country
- CZNC United States
- CMPS United Kingdom
- Employees
- CZNC N/A
- CMPS N/A
- Industry
- CZNC Major Banks
- CMPS Biotechnology: Pharmaceutical Preparations
- Sector
- CZNC Finance
- CMPS Health Care
- Exchange
- CZNC Nasdaq
- CMPS Nasdaq
- Market Cap
- CZNC 330.3M
- CMPS 322.5M
- IPO Year
- CZNC N/A
- CMPS 2020
- Fundamental
- Price
- CZNC $19.68
- CMPS $2.85
- Analyst Decision
- CZNC
- CMPS Strong Buy
- Analyst Count
- CZNC 0
- CMPS 7
- Target Price
- CZNC N/A
- CMPS $21.83
- AVG Volume (30 Days)
- CZNC 24.2K
- CMPS 1.1M
- Earning Date
- CZNC 05-06-2025
- CMPS 05-07-2025
- Dividend Yield
- CZNC 5.55%
- CMPS N/A
- EPS Growth
- CZNC 7.45
- CMPS N/A
- EPS
- CZNC 1.69
- CMPS N/A
- Revenue
- CZNC $106,129,000.00
- CMPS N/A
- Revenue This Year
- CZNC $9.38
- CMPS N/A
- Revenue Next Year
- CZNC $3.77
- CMPS N/A
- P/E Ratio
- CZNC $11.96
- CMPS N/A
- Revenue Growth
- CZNC 1.43
- CMPS N/A
- 52 Week Low
- CZNC $16.50
- CMPS $2.88
- 52 Week High
- CZNC $22.68
- CMPS $10.31
- Technical
- Relative Strength Index (RSI)
- CZNC 45.16
- CMPS 31.09
- Support Level
- CZNC $20.24
- CMPS $2.88
- Resistance Level
- CZNC $20.71
- CMPS $3.16
- Average True Range (ATR)
- CZNC 0.44
- CMPS 0.22
- MACD
- CZNC 0.01
- CMPS -0.03
- Stochastic Oscillator
- CZNC 42.14
- CMPS 3.54
About CZNC Citizens & Northern Corp
Citizens & Northern Corp is a community bank operating through its subsidiaries. It provides banking services, including deposit and loan products for personal and commercial customers. The bank also maintains a trust division that provides a wide range of financial services, such as 401(k) plans, retirement planning, estate planning, estate settlements and asset management.
About CMPS COMPASS Pathways Plc American Depository Shares
Compass Pathways PLC is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The company is motivated by the need to find ways to help and empower people suffering with mental health challenges who are not helped by existing therapies and are pioneering the development of a new model of psilocybin therapy, in which psilocybin is administered in conjunction with psychological support. Its focus is on treatment-resistant depression, or TRD, a subset of depressive disorder, or MDD, comprising patients who are inadequately served by the treatment paradigm. It has developed a proprietary, high-purity polymorphic crystalline formulation of psilocybin, COMP360.